MYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned Listing

VANCOUVER, BC, Jan. 7, 2021 /PRNewswire/ - MYND Life Sciences Inc. ("MYND") a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce the closing of a non-brokered private placement offering by the Company (the "Offering) of an aggregate of 8,000,000 common shares (the "Common Shares") at a price of CDN$0.30 per Common Share for aggregate gross proceeds of CDN$2.4 million. The Company intends to use the proceeds of the Offering to advance MYND's research, working capital, general operating expenses and public listing costs. MYND Life Science Inc. is a leading life sciences company focussed on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.
（以上内容由医药魔方AI生成）